Paradigm Biopharmaceuticals
11:45 AM - 12:00 PM (EDT), Tuesday, June 6, 2023 ・ Session Room 104C
Paradigm Biopharmaceuticals Ltd. (ASX:PAR) is a late-stage drug development company driven by a purpose to improve patients’ health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm’s current focus is developing injectable (subcutaneous) pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3) and mucopolysaccharidosis (phase 2).
Ticker:
PAR
Exchange:
ASX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
Victoria
Company HQ Country:
Australia
Year Founded:
2014
Main Therapeutic Focus:
Inflammation
Lead Product in Development:
injectable pentosan polysulfate sodium
Development Phase of Primary Product:
Phase III
Number Of Unlicensed Products (For Which You Are Seeking Partners):
2
Speaker
